Clinical Trials Browser

Alpelisib × Breast × 1 year × Clear all

Breast Neoplasms

Breast Neoplasms, Genetic Diseases, Inborn

Triple Negative Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Hyperglycemia

Breast Neoplasms, Neoplasm Metastasis

Breast Neoplasms, Melanoma

Breast Neoplasms

Advanced Breast Cancer

Advanced HER2+Breast Cancer

Breast Neoplasms

Breast Neoplasms

HER2-positive Metastatic Breast Cancer

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Neoplasm Metastasis

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies

Breast Neoplasms

Breast Neoplasms

Hormone Receptor Positive Breast Carcinoma

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Hyperglycemia, Neoplasm Metastasis, Multiple Endocrine Neoplasia Type 1

Breast Neoplasms

Clinical Trials

EPIK-B5

SEQUEL-Breast

EPIK-B3

INAVO121

Utilizing Continuous Glucose Monitoring to Characterize and Manage Hyperglycemia in Patients Initiating Alpelisib

ASSET

Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA)

Managed Access Programs for BYL719, Alpelisib

Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer

EPIK-B2

Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer

Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer

Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.

SPEAR

Umbrella Trial of Subtype-Targeted Therapies in ER+/HER2- Breast Cancer

VIKTORIA-1

BYLieve

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

ELEVATE

Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer

A NIS of Alpelisib in Combination With Fulvestrant in Postmenopausal Women, and Men, With HR+,HER2- , Locally Advanced or Metastatic Breast Cancer With a PIK3CA Mutation, After Disease Progression Following Endocrine Therapy as Monotherapy, in the Real-world Setting

AMEERA-1

Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer

Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer

Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations

ALPHABET

SAFIR 03

METALLICA

A Post Marketing Surveillance on Piqray in Korea